Want to see IN:VIMTALABS full AI Analyst Report?
VIMTALABS Stock Chart & Stats
₹609.25
-₹18.70(-1.83%)
At close: 4:00 PM EST
₹609.25
-₹18.70(-1.83%)
Day’s Range― - ―
52-Week Range₹377.30 - ₹902.85
Previous CloseN/A
Volume71.13K
Average Volume (3M)22.50K
Market Cap
₹28.57B
Enterprise Value₹16.76K
Total Cash (Recent Filing)₹664.70M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)35.3
Beta1.05
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)17.86
Shares Outstanding44,686,905
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetThe company's near-zero leverage and rising equity provide durable financial flexibility. Low debt reduces interest burdens and default risk, enabling steady investment in lab capacity, regulatory compliance, or M&A without stressing cash flow during cyclical slowdowns.
Regulatory-driven, Recurring Revenue ModelServing pharma, food, environmental and industrial clients with compliance and testing creates repeatable, mission-critical demand. Regulatory and certification needs generate recurring tests and retainers, supporting predictable mid-term revenue and high client stickiness.
Healthy Margins And Steady Revenue GrowthSustained double-digit revenue growth alongside mid-to-high teen net margins and mid-30% EBITDA shows pricing power and operational efficiency. That margin profile supports internal reinvestment and long-term cash generation for capacity expansion and service quality retention.
Bears Say
Margin VolatilityNotable swings in gross and operating margins imply exposure to mix shifts, pricing pressure, or variable input costs. Persistent volatility makes long-term profitability less predictable, complicating capital allocation, pricing strategy and the sustainability of current margin levels.
Uneven Free Cash Flow ConversionInconsistent FCF and working-capital sensitivity mean cash available for capex, dividends or acquisitions can swing year-to-year. This reduces financial resilience and may necessitate external funding or delayed investments during periods of negative conversion.
Returns Not ExpandingStable mid-teens ROE shows competency but limited improvement over time. Stagnant return metrics suggest constrained incremental capital efficiency, which could limit shareholder return upside and indicates challenges scaling margins or reinvestment returns sustainably.
Vimta Labs Limited News
VIMTALABS FAQ
What was Vimta Labs Limited’s price range in the past 12 months?
Vimta Labs Limited lowest stock price was ₹377.30 and its highest was ₹902.85 in the past 12 months.
What is Vimta Labs Limited’s market cap?
Vimta Labs Limited’s market cap is ₹28.57B.
When is Vimta Labs Limited’s upcoming earnings report date?
Vimta Labs Limited’s upcoming earnings report date is Nov 14, 2026 which is in 84 days.
How were Vimta Labs Limited’s earnings last quarter?
Vimta Labs Limited released its earnings results on Jul 20, 2026. The company reported ₹4.66 earnings per share for the quarter, missing the consensus estimate of ₹445.976 by -₹441.316.
Is Vimta Labs Limited overvalued?
According to Wall Street analysts Vimta Labs Limited’s price is currently Overvalued.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.32%. See more information on Vimta Labs Limited dividends here
What is Vimta Labs Limited’s EPS estimate?
Vimta Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vimta Labs Limited have?
Vimta Labs Limited has 44,686,905 shares outstanding.
What happened to Vimta Labs Limited’s price movement after its last earnings report?
Vimta Labs Limited reported an EPS of ₹4.66 in its last earnings report, missing expectations of ₹445.976. Following the earnings report the stock price went down -5.085%.
Which hedge fund is a major shareholder of Vimta Labs Limited?
Currently, no hedge funds are holding shares in IN:VIMTALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimta Labs Limited
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―